Population Pharmacokinetics of Tobramycin in Patients With and Without Cystic Fibrosis

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: id:"swepub:oai:DiVA.org:uu-201262" > Population Pharmaco...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Hennig, StefanieUppsala universitet,Institutionen för farmaceutisk biovetenskap (author)

Population Pharmacokinetics of Tobramycin in Patients With and Without Cystic Fibrosis

Article/chapterEnglish2013

Publisher, publication year, extent ...

2013-02-19
Springer Science and Business Media LLC,2013
printrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:uu-201262
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-201262URI
https://doi.org/10.1007/s40262-013-0036-yDOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

Background and Objectives While several studies have examined the pharmacokinetics of tobramycin in patients with cystic fibrosis (CF), there is no consensus on whether they differ in patients with and without CF. The objectives of this study were to identify covariates which explain pharmacokinetic variability and to examine whether having the disease CF in itself alters these relationships and drug dose requirements. Methods To investigate this issue, a population pharmacokinetic meta-analysis of data from eight centres was undertaken. NONMEM (R) 7.2 was used to analyse the data, which comprised 4,514 concentration-time measurements from 465 adults and children with CF and 1,095 concentration-time measurements from 267 adults and children without CF. Results Tobramycin disposition was well described by a two-compartment model with first-order elimination. Patient age, fat-free mass, serum creatinine concentration and sex were identified as significant covariates in the final model. Fat-free mass was superior to total bodyweight as a descriptor of clearance, volume of distribution of the central and peripheral compartments and inter-compartmental clearance. CF as an independent disease-specific factor had no significant influence on the pharmacokinetics of tobramycin at any stage during covariate model building. An optimal dose of 11 mg/kg every 24 h was defined for CF patients using a utility function approach. Conclusion The pharmacokinetics of tobramycin do not differ significantly in CF patients compared with patients without CF when subject age, fat-free mass, sex and renal function are taken into consideration. Variations in tobramycin dosing between CF and non-CF patients should therefore reflect target concentrations or exposures based on differences in expected pathogen sensitivity and not the presence of CF.

Added entries (persons, corporate bodies, meetings, titles ...)

Standing, Joseph F.Uppsala universitet,Institutionen för farmaceutisk biovetenskap (author)
Staatz, Christine E. (author)
Thomson, Alison H. (author)
Uppsala universitetInstitutionen för farmaceutisk biovetenskap (creator_code:org_t)

Related titles

In:Clinical Pharmacokinetics: Springer Science and Business Media LLC52:4, s. 289-3010312-59631179-1926

Internet link

Find in a library

Clinical Pharmacokinetics (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Hennig, Stefanie; Standing, Joseph ...; Staatz, Christin ...; Thomson, Alison ...

Articles in the publication: Clinical Pharmac ...

By the university: Uppsala University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se